Entero Healthcare divests subsidiary, acquires medical device firm stake

Entero Healthcare Solutions Limited announced its Board of Directors approved the sale of its entire 100% stake in Suprabhat Pharmaceutical Private Limited, a wholly-owned subsidiary. The consideration for this sale is up to INR 37,00,000. Suprabhat's income contributed 0.39% and net worth contributed 0.01% to Entero's consolidated financials as of March 31, 2025. The buyers were erstwhile promoters of Suprabhat, and the transaction is considered an Arm's Length related party transaction.

Concurrently, Entero Healthcare also approved the acquisition of a 60% stake in Ace Cardiopathy Solutions Private Limited, a target company engaged in the wholesale distribution of medical devices and other healthcare products. The acquisition cost is expected to range between INR 59.30 Crore and INR 77.10 Crore, subject to adjustments. Ace Cardiopathy's turnover for FY 2024-2025 was INR 1548 million.

The acquisition of Ace Cardiopathy is expected to be completed by January 31, 2026, and will be funded through cash consideration. The move aligns with Entero Healthcare's business, focusing on the wholesale distribution of medical devices and allied products.